Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Features and protective efficacy of human mAbs targeting Mycobacterium tuberculosis arabinomannan
Yanyan Liu, Tingting Chen, Yongqi Zhu, Aisha Furey, Todd L. Lowary, John Chan, Stylianos Bournazos, Jeffrey V. Ravetch, Jacqueline M. Achkar
Yanyan Liu, Tingting Chen, Yongqi Zhu, Aisha Furey, Todd L. Lowary, John Chan, Stylianos Bournazos, Jeffrey V. Ravetch, Jacqueline M. Achkar
View: Text | PDF
Research Article Immunology Infectious disease

Features and protective efficacy of human mAbs targeting Mycobacterium tuberculosis arabinomannan

  • Text
  • PDF
Abstract

A better understanding of the epitopes most relevant for antibody-mediated protection against tuberculosis (TB) remains a major knowledge gap. We have shown that human polyclonal IgG against the Mycobacterium tuberculosis (M. tuberculosis) surface glycan arabinomannan (AM) and related lipoarabinomannan (LAM) is protective against TB. To investigate the impact of AM epitope recognition and Fcγ receptor (FcγR) binding on antibody functions against M. tuberculosis, we isolated a high-affinity human monoclonal antibody (mAb; P1AM25) against AM and showed its binding to oligosaccharide (OS) motifs we previously found to be associated with in vitro functions of human polyclonal anti-AM IgG. Human IgG1 P1AM25, but not 2 other high-affinity human IgG1 anti-AM mAbs reactive with different AM OS motifs, enhanced M. tuberculosis phagocytosis by macrophages and reduced intracellular growth in an FcγR-dependent manner. P1AM25 in murine IgG2a, but neither murine IgG1 nor a non–FcγR-binding IgG, given intraperitoneally prior to and after aerosolized M. tuberculosis infection, was protective in C57BL/6 mice. Moreover, we demonstrated the protective efficacy of human IgG1 P1AM25 in passive transfer with M. tuberculosis–infected FcγR-humanized mice. These data enhance our knowledge of the important interplay between both antibody epitope specificity and Fc effector functions in the defense against M. tuberculosis and could inform development of vaccines against TB.

Authors

Yanyan Liu, Tingting Chen, Yongqi Zhu, Aisha Furey, Todd L. Lowary, John Chan, Stylianos Bournazos, Jeffrey V. Ravetch, Jacqueline M. Achkar

×

Figure 1

The human mAb P1AM25 reacts strongly with diverse and distinct glycan motifs within AM/LAM.

Options: View larger image (or click on image) Download as PowerPoint
The human mAb P1AM25 reacts strongly with diverse and distinct glycan mo...
(A) Gating of IgG+AM+ B cells from PBMCs of participant P1 by fluorescence-activated cell sorting (full set of gating images shown in Supplemental Figure 1). (B) Polyclonal serum IgG reactivity of participant P1 (1:100; gray bars) and mAb P1AM25 (1 μg/mL; red bars) to 30 synthetic mycobacterial AM OS motifs. Median fluorescence intensity (MFI) is shown for AM OS with numbers corresponding to position on glycan array. Specifically, P1AM25 reacts strongly with the following OS motifs organized by groups according to location within AM as shown in C and framed in red (adapted from refs. 29, 52): I) mannose-capped (Man Cap) motifs Man1Ara4 (OS#2), Man2Ara4 (OS#3), and Man3Ara4 (OS#4); II) MTX-Manp cap motifs MTX1Man2Ara4 (OS#7), MTX1Man1Ara4 (OS#8), and MTX1Man3Ara4 (OS#9); III) core Man motifs Ara5Man4 (OS#56) and Ara5Man3 (OS#57); V) myoinositol-phosphate (PI) cap motif PI1Ara4 (OS#49); VI) terminal Ara motifs Ara4 (OS#1), Ara8 (OS#15), Ara7 (OS#16), Ara10 (OS#18), Ara11 (OS#20), and Ara22 (OS#22); and VII) Core Ara Motifs Ara16 (OS#19) and Ara18 (OS#21). (C) Binding curve of P1AM25 to capsular AM (isolated from H37Rv) by BLI. KD = 3.4 × 10–9 M. Experimental data are shown as solid lines, and statistically fitted curves are shown as dashed lines. (D) Structural OS motifs organized into groups based on location within AM/LAM (adapted from refs. 29, 30, 72). OS motifs strongly recognized by P1AM25 are framed in red and for comparison shown for the human anti-AM mAbs T1AM09 (blue) and L1AM04 (green). Solid lines represent strong and dashed weak binding (glycan array of T1AM09 and L1AM04 performed in ref. 33). Data are representative of 2 independent experiments.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts